EydisBio, Inc.

EydisBio, Inc. is a dynamic biopharmaceutical company dedicated to the research and development of innovative small molecule therapeutics. Focusing on autoimmune and inflammatory diseases, EydisBio, Inc. aims to address significant unmet medical needs with highly potent and selective treatments. The company's leading TAK1 inhibitor program is specifically designed to help the large percentage of rheumatoid arthritis patients who do not respond or lose response to anti-TNF biologics.

Located at 201 West Main Street, Durham, North Carolina 27701-3228, US, EydisBio, Inc. is also exploring applications of its orally bioavailable TAK1 inhibitors in other autoimmune conditions such as systemic sclerosis and viral-induced acute respiratory distress syndrome. Furthermore, EydisBio, Inc. is investigating its inhibitors as a potential alternative to opioids for chronic pain management. These efforts highlight the company's commitment to pioneering solutions for challenging medical conditions.

In addition to its autoimmune and inflammatory disease programs, EydisBio, Inc. has an oncology discovery program showing early promise in treating patients with FLT3 mutation-positive AML and glioblastoma. With a strong focus on research and development, EydisBio, Inc. is poised to make a significant impact in the biopharmaceutical industry. We invite the manager of EydisBio, Inc. to take advantage of the opportunity to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial reach.